An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

• Status: Completed
• Trial end date: 2021-08-12
• Target enrollment: 0
• Participant gender: All

Summary

This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: United Therapeutics
• Treatments: Treprostinil

Criteria

Inclusion Criteria:

• Participated in United Therapeutics Study TDE-PH-310

Exclusion Criteria:

• Premature discontinuation of United Therapeutics Study TDE-PH-310 due to reasons other than clinical worsening